Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
67.60 x 1 68.38 x 1
Post-market by (Cboe BZX)
68.46 -5.46 (-7.39%) 04/04/25 [NASDAQ]
67.60 x 1 68.38 x 1
Post-market 68.46 unch (unch) 16:27 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
68.43
Day High
72.05
Open 71.75
Previous Close 73.92 73.92
Volume 7,863,815 7,863,815
Avg Vol 5,322,901 5,322,901
Stochastic %K 14.14% 14.14%
Weighted Alpha -4.47 -4.47
5-Day Change -5.33 (-7.22%) -5.33 (-7.22%)
52-Week Range 62.75 - 87.68 62.75 - 87.68
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 229,241,744
  • Shares Outstanding, K 3,101,214
  • Annual Sales, $ 54,073 M
  • Annual Income, $ 7,035 M
  • EBIT $ 10,003 M
  • EBITDA $ 16,691 M
  • 60-Month Beta 0.49
  • Price/Sales 4.14
  • Price/Cash Flow 11.47
  • Price/Book 5.48

Options Overview Details

View History
  • Implied Volatility 38.65% ( +7.71%)
  • Historical Volatility 28.42%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 38.65% on 04/04/25
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 10,338
  • Volume Avg (30-Day) 7,368
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 189,088
  • Open Int (30-Day) 182,682

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.10
  • Number of Estimates 5
  • High Estimate 1.14
  • Low Estimate 1.07
  • Prior Year 1.03
  • Growth Rate Est. (year over year) +6.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.43 +0.04%
on 04/04/25
Period Open: 77.25
78.36 -12.63%
on 03/05/25
-8.79 (-11.38%)
since 03/04/25
3-Month
64.22 +6.60%
on 01/14/25
Period Open: 66.25
78.36 -12.63%
on 03/05/25
+2.21 (+3.34%)
since 01/03/25
52-Week
62.75 +9.10%
on 11/18/24
Period Open: 67.34
87.68 -21.92%
on 08/30/24
+1.12 (+1.66%)
since 04/04/24

Most Recent Stories

More News
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the expanded...

AZN : 68.46 (-7.39%)
JNJ : 153.24 (-4.12%)
NVS : 105.85 (-5.71%)
PFE : 22.97 (-5.43%)
SNY : 51.98 (-4.83%)
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading...

AZN : 68.46 (-7.39%)
$SPX : 5,074.08 (-5.97%)
VEEV : 213.68 (-3.53%)
CPRX : 23.07 (-4.31%)
AMGN : 294.39 (-4.99%)
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small...

AZN : 68.46 (-7.39%)
JNJ : 153.24 (-4.12%)
NVS : 105.85 (-5.71%)
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

AZN : 68.46 (-7.39%)
LLY : 738.21 (-6.45%)
NVS : 105.85 (-5.71%)
ATNM : 1.2900 (-7.19%)
BMY : 55.30 (-4.36%)
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule Lipoprotein(a)...

AZN : 68.46 (-7.39%)
NVO : 62.55 (-6.78%)
MRK : 81.47 (-5.70%)
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing well...

COMP : 8.28 (-1.78%)
AZN : 68.46 (-7.39%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 68.46 (-7.39%)
JNJ : 153.24 (-4.12%)
NVS : 105.85 (-5.71%)
PFE : 22.97 (-5.43%)
SNY : 51.98 (-4.83%)
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor,...

AZN : 68.46 (-7.39%)
JNJ : 153.24 (-4.12%)
LLY : 738.21 (-6.45%)
ABBV : 186.96 (-7.28%)
Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

This week, Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants. AstraZeneca’s AZN phase III study on breast cancer candidate, camizestrant,...

AZN : 68.46 (-7.39%)
MRK : 81.47 (-5.70%)
LLY : 738.21 (-6.45%)
3 Magnificent Growth Stocks to Buy Right Now

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. But which stocks are likely to deliver growth over the next...

AZN : 68.46 (-7.39%)
VRTX : 474.62 (-1.94%)
LLY : 738.21 (-6.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 76.95
2nd Resistance Point 76.33
1st Resistance Point 75.12
Last Price 68.46
1st Support Level 73.29
2nd Support Level 72.67
3rd Support Level 71.46

See More

52-Week High 87.68
Fibonacci 61.8% 78.15
Fibonacci 50% 75.21
Fibonacci 38.2% 72.27
Last Price 68.46
52-Week Low 62.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades